Addressing CNS Metastases in HER2-Positive Breast Cancer

Watch Dr. VK Gadi and Dr. Anne O’Dea address handling central nervous system (CNS) metastases in HER2-positive metastatic breast cancer. Doctors worry about CNS cancer and discuss their surveillance and treatment plans. CNS involvement is important for considering second-line therapy, especially if patients have CNS-only or CNS-predominant disease.

Key topics are the HER2CLIMB trial regimen and the the rising efficacy of ADCs like T-DXd (trastuzumab deruxtecan) in CNS metastases. The balance between proactive CNS monitoring and symptom-driven surveillance in patients with HER2-positive breast cancer is also discussed. Both doctors strongly believe in seeking individualized methods based on patient complaints, illness progression, and new therapy findings.